28 results about "Immunity disorders" patented technology

The present invention discloses a strain of Lactobacillus paracasei that simultaneously activates immune regulation and antioxidant pathways to alleviate vaginitis, belonging to the field of microbial technology. The present invention screened and obtained a strain of Lactobacillus paracasei CCFM1316, which has the effect of repairing related symptoms such as immune disorders and oxidative damage caused by vaginitis, specifically embodied in: reducing cellular NF-κB mRNA expression and cell supernatant IL-1β content, improving mouse vaginal immune response, enhancing mouse vaginal antioxidant capacity, improving mouse vaginal pathological manifestations and reducing pathogenic bacteria load. It reduces the mouse vaginal Gardnerella load and improves mouse vaginal pathological manifestations; therefore, Lactobacillus paracasei CCFM1316 has great application prospects in products that improve and repair immune disorders and oxidative damage problems caused by vaginitis.

The invention relates to the field of new application of traditional Chinese medicinal materials, and particularly provides application of ash grass root in preparation of medicine for treating ulcerative colitis, DSS-induced mouse colitis model experiments and UC patient control experiments show that ash grass root has remarkable technical effects in treatment of ulcerative colitis, and the application of ash grass root in preparation of medicine for treating ulcerative colitis in preparation of medicine for treating ulcerative colitis in preparation of medicine for treating ulcerative colitis. The gray couchgrass root shows the effect of relieving inflammatory response, tissue damage and immune disorder related to colitis; the intestinal mucosa repair is promoted; the intestinal barrier function is strengthened; the pathological state of colon tissue is improved; the level of inflammatory factors is reduced; and flora metabolism can be adjusted. The invention provides a new natural medicine source for preventing and treating ulcerative colitis, and has good application value and industrial transformation prospect.

The invention relates to the technical field of primary local hyperhidrosis, in particular to a biomarker for detecting primary local hyperhidrosis and application of the biomarker, and the biomarker comprises but is not limited to one or more of the ratio of Th17 cells to Treg cells, IL-17A, IL-6, ROR gamma t and FoxP3. According to the invention, a multi-dimensional detection system covering PFH core pathological links (immune disorder, hyperactivity of sympathetic nerves and hyperfunction of sweat gland) is constructed by integrating immune related markers such as Th17 / Treg cell ratio, IL-17A, IL-6, ROR [gamma] t, FoxP3 and the like and combining the concentrations of peripheral blood epinephrine (E) and noradrenaline (NE) and the gene expression levels of sweat gland tissues AQP5 and Cacna1c. And a potential molecular target is provided for developing a novel therapeutic strategy (such as specific blocking of an IL-17 signal channel or enhancement of a Treg function) of a targeted Th17 / Treg axis.

The invention belongs to the technical field of skin disease treatment and medicine, and particularly relates to an external pharmaceutical composition for treating atopic dermatitis and a preparation method and application thereof. The medicine composition is liquid medicine composed of blumea balsamifera oil, perfoliote knotweed herb and piper cubeba extract and is specially used for treating the atopic dermatitis (AD). According to the composition, the blumea balsamifera oil is innovatively used as a main component and cooperates with the perfoliote knotweed herb and the piper cubeba extract to form an efficient treatment scheme, and the curative effect of the composition is remarkably superior to that of a traditional method for singly using the blumea balsamifera oil. Experiments prove that the composition can effectively improve the skin barrier function, regulate immune disorder, reduce the levels of serum IgE and TSLP and inflammatory factors IL-4 and IFN-gamma, and reduce inflammatory cell infiltration, so that the AD symptom is relieved, and the recurrence rate is reduced.

The invention provides an application of lactobacillus rhamnosus in preparation of a probiotic preparation for regulating weightlessness immune disorder. The application of the lactobacillus rhamnosus in preparation of the probiotic preparation for regulating weightlessness immune disorder proves that the lactobacillus rhamnosus can regulate immune disorder caused by tail suspension simulation weightlessness and can be used for preparing the probiotic preparation for preventing or treating weightlessness immune disorder, a novel probiotic preparation is provided, and the lactobacillus rhamnosus can be used for preparing the probiotic preparation for preventing or treating weightlessness immune disorder. The medicine is suitable for preventing and treating immune diseases generated by astronauts subjected to long-term or short-term space flight.

The invention belongs to the technical field of animal nutrition and feed, discloses an application of a Fuzhuan tea extract in prevention of vomitoxin-caused piglet health injury, and particularly relates to an application of the Fuzhuan tea extract as a feed additive in prevention or improvement of piglet health injury. The feed additive can effectively reduce negative effects on weaned piglets caused by excessive vomitoxin in the feed, wherein the negative effects comprise growth performance reduction, diarrhea rate increase, intestinal morphology damage, intestinal cell proliferation inhibition, intestinal epithelial barrier injury, immune disorder, abnormal liver function and excessive oxidative stress and inflammatory response.

The purpose of the present invention is to control the number of peripheral regulatory T cells in the intestinal tract to thereby establish a novel means for treating a disease relating to the cells. For this purpose, provided is a therapeutic drug for a disease, said drug comprising a substance capable of controlling the number of peripheral regulatory T cells in the intestinal tract and being characterized in that the aforesaid substance is an activator or suppressor of the hepatic branch of vagal afferent pathway, an activator or suppressor of left vagal efferent pathway, or an agonist or antagonist of muscarinic acetylcholine receptor.

To regulate the number of peripheral regulatory T cells in the intestinal tract and to provide a new means for treating diseases associated with the cells.SOLUTION: A therapeutic agent for a disease, comprising a substance having an effect of regulating the amount of peripheral regulatory T cells in the intestinal tract, wherein the substance is a substance that activates or suppresses the hepatic vagal afferent pathway, a substance that activates or suppresses the left vagal efferent pathway, or an agonist or antagonist of a muscarinic acetylcholine receptor.SELECTED DRAWING: None

The invention relates to a lactobacillus paracasei K56 metagen and application of the lactobacillus paracasei K56 metagen in the aspect of controlling in-vivo fat, and particularly provides one or more applications of the lactobacillus paracasei K56 metagen selected from the group consisting of the following beneficial intestinal bacteria: the lactobacillus paracasei K56 metagen is used for promoting the proliferation of the beneficial intestinal bacteria, the beneficial intestinal bacteria are selected from one or more of norkfRuminococcus, Lactobacillus and Coriobacterium UCG-002, preferably one or more of norkfRuminococcus and Coriobacterium UCG-002, and the lactobacillus paracasei K56 metagen is used for promoting the proliferation of the beneficial intestinal bacteria, preferably one or more of the norkfRuminococcus, Lactobacillus and Coriobacterium UCG-002. The composition is used for regulating obesity (such as obesity caused by high-fat diet); for modulating (e.g., caused by high fat diet) lipid metabolism disorders and / or liver lipid accumulation; for modulating (e.g., caused by high fat diet) colon immune disorders; wherein the lactobacillus paracasei K56 is preserved in the German Colletion of Microorganisms and Cell Cultures, the preservation number of the lactobacillus paracasei K56 is DSM 27447, and the lactobacillus paracasei K56 is preserved in the German Microorganism Preservation Center (MCC), the preservation number of the lactobacillus paracasei K56 is DSM 27447, and the preservation number of the lactobacillus paracasei K56 is CGMCC NO. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number of the strain is CGMCC 15139, and the strain is also preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the strain is CGMCC 15139.

To provide an anti-blood dendritic cell antigen 2 antibody and its use. [Solution] Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods for using the above antibodies and antibody fragments to induce plasmacytoid dendritic cell death, inhibit the production or secretion of inflammatory cytokines and chemokines, and treat or prevent immune disorders such as inflammatory and autoimmune conditions. (i) an isolated antibody or its antigen-binding fragment that selectively binds to the extracellular domain of human BDCA2, and (ii) competes with BIIB059 for binding to the extracellular domain of human BDCA2.

The present invention provides an anti-CXCR6 antibody and the use thereof. The anti-CXCR6 antibody can bind to CXCR6 with high affinity and high specificity, has cross-species binding activity to both human CXCR6 and monkey CXCR6, is a clearing antibody targeting CXCR6, and has the potential of treating inflammation or immune disorder diseases. Compared with existing CXCR6 antibodies, the anti-CXCR6 antibody involves lower cell non-specific binding activity, lower off-target toxicity and higher safety.

The invention discloses Yao-strengthening ointment for improving immune disorder of an HIV infected person. The Yao-strengthening ointment is mainly prepared from the following raw materials: astragalus membranaceus, poria cocos, rhizoma cimicifugae, radix achyranthis bidentatae, roasted ephedra, prepared radix aconiti carmichaeli, asarum, roasted liquorice, philippine flemingia root, giantleaf ardisia rhizome, caulis sinomenii, tripterygium wilfordii and gynostemma pentaphylla. The preparation method of the Zhuang Yao ointment comprises the steps of medicinal material treatment, medicinal material extraction and ointment preparation. The whole formula is mainly used for strengthening the body resistance (tonifying qi and warming yang) and eliminating evil (dehumidifying, activating blood and detoxifying), through the compatibility of monarch, minister, assistant and guide, the traditional Chinese medicine aims at core qi deficiency and yang deficiency of immune disorder of HIV infected people and also eliminates pathological products such as dampness, stasis and heat toxin, meanwhile, honey-fried licorice root is used for regulating the medicine property, CD4 cells of the HIV infected people can be improved, immune disorder can be improved to a certain extent, and immune reconstitution is promoted.

The invention relates to the technical field of traditional Chinese medicines, and particularly discloses application of a traditional Chinese medicine composition in preparation of a medicine for treating or preventing severe pneumonia. Researches prove that the traditional Chinese medicine composition can relieve lung injury and inflammation of a severe pneumonia mouse model, improve lung cell factor level abnormity and reverse immune disorder caused by activation of macrophages and depletion of lymphocytes of the severe pneumonia mouse. The traditional Chinese medicine composition can protect lung capillaries and prevent severe pneumonia. Clinical tests prove that all the medicinal materials of the traditional Chinese medicine composition act together, and the traditional Chinese medicine composition shows a remarkable clinical curative effect on severe pneumonia patients.

The application discloses a composition for relieving vaginitis by simultaneously activating immune regulation and antioxidant pathways, and belongs to the technical field of microorganisms. The application screens a composite strain containing a strain of Paracaseolovis casei CCFM1316 and a strain of Paracaseolovis casei CCFM1317, and the composition containing the composite strain has the effect of repairing immune disorders, oxidative damage and other related symptoms caused by vaginitis, which is specifically embodied in: regulating the immune response of the mouse vagina; activating the TLR-4 / MyD88 pathway, and reducing the IL-1beta concentration of the vaginal tissue to 29.79 ng / L; improving the oxidative stress of the mouse vagina; and increasing the Nrf2 of the vaginal tissue to 36.58 ng / L. Therefore, the composition of the Paracaseolovis casei CCFM1316 and the Paracaseolovis casei CCFM1317 has great application prospect in products for improving and repairing the inflammatory response and oxidative damage caused by vaginitis.

The invention discloses application of yellow tea polyphenol in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of biological medicine preparation, animal experiments prove that the yellow tea polyphenol can reduce the DAI index of DSS-induced colitis mice and relieve weight loss and colon shortening. By adopting the yellow tea polyphenol provided by the invention, inflammatory response, tissue damage and immune disorder related to colitis can be relieved; the pathological state of colon tissue is improved; therefore, the effect of treating and preventing the colitis is achieved, and the traditional Chinese medicine composition has an extremely wide application prospect.

The invention discloses a double-membrane independently wrapped nano drug delivery system for regulating macrophages and platelets. The nano drug delivery system comprises macrophage membrane coated nanoparticles and platelet membrane coated nanoparticles, the macrophage membrane coated nanoparticles are used for adjusting macrophage immune response and loaded with a Toll-like receptor 7 (TLR7) inhibitor, the platelet membrane coated nanoparticles are used for inhibiting abnormal activation of platelets and loaded with a G protein coupled receptor P2Y12 inhibitor, the TLR7 inhibitor comprises at least one of TJ-M2010-5, hydroxychloroquine, Enpatron and IMO-8400, and the TLR7 inhibitor comprises at least one of TJ-M2010-5, hydroxychloroquine, Enpatron and IMO-8400. The P2Y12 inhibitor is prepared from at least one of ticagrelor, clopidogrel, prasugrel and cangrelor. According to the double-membrane independently-wrapped nano drug delivery system, drugs are efficiently delivered to related damaged cells of an inflammation part by utilizing related cell tropism of two cell membranes, immune disorder caused by macrophage and platelet abnormality is inhibited, diseases induced by immune imbalance are treated, an immune microenvironment is regulated and controlled, and the drug delivery effect is improved. And a new direction is provided for treatment of immune diseases.

This invention belongs to the field of biomedical technology, specifically relating to an umbilical cord MSC exosome nanocarrier delivery system and its application in the preparation of drugs for treating allergic rhinitis. This invention prepares the umbilical cord MSC exosome nanocarrier delivery system by adding a specific concentration of diosgenin to the culture medium of umbilical cord mesenchymal stromal cells (MSCs), collecting the cell culture supernatant, and separating and extracting it. Animal experiments show that the delivery system prepared in this invention significantly improves the symptoms of nose scratching and sneezing in mice with allergic rhinitis. Its mechanism of action lies in effectively regulating the Th1 / Th2 immune balance: significantly inhibiting the overexpression of the pro-inflammatory factor IL-4, while simultaneously restoring the anti-inflammatory factor IL-10, thus avoiding immune dysregulation. This invention provides a safe and effective new treatment for allergic rhinitis and has good clinical application prospects.

The application discloses lactobacillus johnsonii capable of orally assisting in relieving vaginitis and improving skin aging, and belongs to the technical field of microorganisms.The lactobacillus johnsonii is separated from vaginal secretions of healthy women, has the effects of repairing immune disorders caused by vaginitis and skin aging of mice with vaginitis, and is specifically reflected in the following aspects: reducing the content of IL-1beta in cell supernatant; improving inflammatory reactions of mouse vaginas; reducing the expression of TLR-4 mRNA and the level of TNF-alpha in vaginal tissues; enhancing the anti-aging ability of mouse skin; reducing the expression of MAPK / AP-1 / MMP-1 mRNA, increasing the content of Col I and Col III in skin; improving pathological characteristics of mouse vaginas and reducing the load of pathogenic bacteria.Therefore, the lactobacillus johnsonii has great application prospects in products for improving and repairing inflammatory damage caused by vaginitis and skin health problems of mice with vaginitis.

The invention belongs to the technical field of medicines, and discloses application of baicalein in preparation of related medicines for treating human coronavirus 229E infected pneumonia. Specifically, the invention discloses application of baicalein in preparation of medicines playing a protective role in prevention and / or treatment of respiratory dysfunction, lung injury, inflammatory response, virus infection and immune disorder caused by human coronavirus 229E infected pneumonia. Pharmacological experiments prove that baicalein can improve the respiratory function in human coronavirus 229E infected pneumonia, exert anti-inflammatory, anti-virus and immunoregulation effects, and can improve pulmonary edema, thereby achieving the purpose of treatment.

The invention belongs to the technical field of medicines, and discloses application of a Dayuan drink extract in related medicines for treating human coronavirus 229E infected pneumonia. Specifically, the invention discloses application of a Dayuan drink extract in preparation of drugs for protecting respiratory dysfunction, lung injury, inflammatory response, virus infection and immune disorder caused by human coronavirus 229E infected pneumonia. Pharmacological experiments prove that the Dayuan drink extract can improve the respiratory function in human coronavirus 229E infected pneumonia, exert anti-inflammatory, antiviral and immunoregulation effects, and can improve pulmonary edema, thereby achieving the purpose of treatment.

The present invention refers to an oligonucleotide comprising 15 to 22 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with pre-mRNA of mixed lineage kinase domain like pseudokinase (MLKL) derived from SEQ ID NO.1289 (GRCh38.p 14: 16:74671855-74700960) or mRNA of MLKL derived from SEQ ID NO.1290 (RefSeq ID NM_152649.4). The invention is further directed to a pharmaceutical composition comprising such oligonucleotide. The pharmaceutical composition and the oligonucleotide are for use in a method of preventing and / or treating a hyperproliferative disorder, an inflammatory or autoimmune disorder, neurodegenerative disease, a neurological disorder, cardiovascular, metabolic disorder, renal disorder, liver disorder, lung disorder, skin disorder, ocular disorder, disorder of the gastro-intestinal tract, joint inflammation, organ malfunction after organ transplantation, fibrotic disorder and a combination thereof inflammatory disease, cancer, an ophthalmic disease, an autoimmune disorder and / or an immune disorder.

The invention relates to the technical field of medicines, and particularly discloses a laggera alata extract-containing composition for treating rheumatoid arthritis and a preparation method thereof. The laggera alata extract-containing composition for treating rheumatoid arthritis is prepared from the following raw materials in parts by weight: 20 to 40 parts of laggera alata extract, 5 to 10 parts of curcumin, 3 to 7 parts of icariin, 8 to 15 parts of phosphatidylcholine, 10 to 20 parts of polyethylene glycol-400, 3 to 8 parts of hyaluronic acid, 2 to 5 parts of chitosan and 5 to 12 parts of mannitol. The preparation method comprises the following steps: preparing the extract; preparing a compound; preparing a suspension; and forming the preparation. According to the composition disclosed by the invention, an active system is constructed by adopting the laggera alata extract, curcumin and icariin, synergistic effects are respectively formed aiming at different pathological links such as oxidative stress imbalance of rheumatoid arthritis, abnormal secretion of inflammatory factors, immune disorder and cartilage injury, and the effects of multi-mechanism synchronous intervention and targeted enrichment are achieved.

The invention relates to the technical field of pet nutrition, and particularly discloses a pet immunoregulation feed formula with a multi-source fatty acid synergistic effect as well as a preparation method and application of the pet immunoregulation feed formula. The invention aims to solve the problems of single fatty acid source and unbalanced Omega-6 / Omega-3 proportion (gt; in order to solve the problem of immune disorder caused by EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid) and GLA (gamma-linolenic acid), by optimizing the ratio of EPA (eicosapentaenoic acid) to DHA (docosahexaenoic acid) to GLA (gamma-linolenic acid), a core formula in which the mass ratio of EPA to DHA to GLA is 3: 5: 2 is provided, and the total mass ratio of Omega-6 / Omega-3 is controlled to be 0.5: 1-2: 1. According to the formula, the IgG level of serum of pets, the CD4 < + > / CD8 < + > T cell ratio and the vaccine antibody titer are remarkably improved through a triple synergistic mechanism of anti-inflammation, immune activation and antibody generation. Experiments show that the traditional Chinese medicine composition can reduce chronic inflammation and balance immune response, and has no pathological injury. The feed additive is suitable for pets such as dogs and cats, can be processed into various forms such as granules and wet food, and provides an innovative scheme for development of immune regulation type pet feed.

The present invention provides universal immunotherapy compositions useful for targeted therapy of cancer and other immune disorders.

The invention discloses oral spirulina delivery hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The delivery hydrogel takes spirulina platensis as a raw material, and is added into network-shaped hydrogel formed by xanthan gum / konjac glucomannan / sodium alginate in a combined manner. The method is easy to implement, safe in component and high in encapsulation efficiency. The composite hydrogel has the following effects: after oral administration, the spirulina can be protected to completely pass through the stomach, the intestinal retention is prolonged, and the slow release of the medicine at the focus part is realized; according to the present invention, with the application of the polypeptide, the oxidative stress and the intestinal inflammation can be alleviated, and the expression of the tight junction protein can be significantly recovered so as to enhance the barrier integrity and limit the inflammation leakage, such that the whole body immune homeostasis conversion can be achieved, the good safety and the good compliance can be provided, and the clinical transformation potential as the systemic chronic inflammatory disease adjuvant therapy strategy can be represented; the traditional Chinese medicine composition is especially suitable for diseases with pathological characteristics of intestinal flora imbalance or immune disorder.

The present disclosure provides systems, methods, devices, and kits for analysis of vaginal biological samples. A device for the analysis of vaginal biological samples can include a sample collector, an extractor, and an assay cartridge. A method for the analysis of vaginal biological samples can include detecting the presence or absence of a pathology, a disease, an immune disorder, a reproductive disorder of a subject. The method may further comprise preserving, storing, or transporting the vaginal biological samples. A kit for the analysis of vaginal biological samples can include probe, reagents and instructions for detecting a nucleic acid in the vaginal biological samples.

The invention provides siRNA for inhibiting melanocortin receptor 4 (MC4R) gene expression in human cells, a polypeptide oligonucleotide conjugate and application of the polypeptide oligonucleotide conjugate, the siRNA comprises a positive-sense strand and a corresponding antisense strand, and the nucleotide composition of the siRNA is each group of corresponding positive-sense strand and corresponding complementary antisense strand in a table 1, or a sequence having a difference of no more than 3 nucleotides from its sense strand or antisense strand. According to the invention, a plurality of siRNAs which can be used for inhibiting MC4R expression are screened, and on the basis, proper modification is carried out to improve the silence capability of a target. And moreover, a unique delivery system is adopted to enable the siRNA to be delivered into the brain to play a role, so that the siRNA is expected to be applied to energy metabolism disorder diseases, such as cachexia, sarcopenia, emaciation syndrome and anorexia nervosa, which are clinically related to MC4R target spots, and other consumptive diseases caused by chronic inflammation, cancer and immune disorder, such as cachexia, sarcopenia, emaciation syndrome and anorexia nervosa.

The application relates to the technical field of pharmaceutical preparations, in particular to a sustained-release preparation of isopropyl inosine and a preparation method and application thereof, and the sustained-release preparation of isopropyl inosine comprises a tablet core and a coating film covering the tablet core; wherein the tablet core comprises the following components in percentage by mass: 70%-74.35% of isopropyl inosine, 20%-25% of a hydrophilic gel matrix material, 5%-14.35% of a filling agent, 0.5%-2% of a disintegrating agent and 0.15%-0.5% of a lubricant; the coating film comprises the following components in percentage by mass: 70%-75% of a film control material, 10%-20% of a pore-forming agent and 10%-20% of a plasticizer; the weight of the coating film is 5%-8% of the weight of the tablet core. The application provides the sustained-release preparation of isopropyl inosine and a preparation method and application thereof; the sustained-release preparation of isopropyl inosine plays an anti-inflammatory and joint protection role by regulating T / B lymphocyte activity and inhibiting inflammatory factor release, and makes up for the defects of traditional arthritis treatment drugs, i.e. only relieving symptoms and being unable to regulate immune disorders.